Abstract
Human mitochondria can be genetically distinct within the same individual, a phenomenon known as heteroplasmy. In cancer, this phenomenon seems exacerbated, and most mitochondrial mutations seem to be heteroplasmic. How this genetic variation is arranged within and among normal and tumor cells is not well understood. To address this question, here we sequenced single-cell mitochondrial genomes from multiple normal and tumoral locations in four colorectal cancer patients. Our results suggest that single cells, both normal and tumoral, can carry various mitochondrial haplotypes. Remarkably, this intra-cell heteroplasmy can arise before tumor development and be maintained afterward in specific tumoral cell subpopulations. At least in the colorectal patients studied here, the somatic mutations in the single-cells do not seem to have a prominent role in tumorigenesis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by project No. 32030 awarded to M.F., co-financed by COMPETE 2020, Portugal 2020 and the EU through the ERDF, and by FCT (PTDC/BIA-EVL/32030/2017) through national funds, and by the European Research Council (ERC-617457-PHYLOCANCER awarded to D.P.) and Spanish Ministry of Science, Innovation, and Universities - MCIU (PID2019-106247GB-I00 awarded to D.P.). J.M.C.-T. is supported by grant no. ISCIII‑PI19/01316 from Instituto de Salud Carlos III, State Research Agency and Ministry of Science and Innovation (Spain), with the participation of the European FEDER fund.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Samples included in this study were provided by the Biobanks of the Health Research Institute of Santiago (PT13/0010/0068) and Galicia Sur Health Research Institute (B.0000802), both integrated into the Spanish National Biobank Network. Samples were processed following standard operating procedures with the approval of the Ethical and Scientific Committees (CAEI Galicia 2014/015). Written informed consents were provided by the patients or by their families.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced are available online at https://github.com/anpefi/sc-mtDNA